首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2020年 4期“自身免疫性肝炎” => 专家论坛 =>自身免疫性肝炎的标准..
自身免疫性肝炎的标准治疗和潜在治疗靶点
Standard therapy and potential therapeutic targets for autoimmune hepatitis
文章发布日期:2020年03月11日  来源:  作者:王睿,王绮夏,马雄  点击次数:427次  下载次数:166次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:自身免疫性肝炎(AIH)是一种由自身免疫反应介导的肝脏炎症性疾病,未经积极治疗可发展为肝衰竭、肝硬化。AIH的治疗目标为获得生化缓解和组织学缓解。目前标准治疗方案为免疫抑制剂疗法,即泼尼松(龙)联合硫唑嘌呤或泼尼松(龙)单药治疗。患者对标准治疗方案不耐受或应答不佳时,可考虑启动包括吗替麦考酚酯在内的二线治疗方案。近年来研究表明,免疫功能、肠道菌群、维生素D、心理状态等多种因素参与AIH的发生发展,可作为AIH的潜在治疗靶点。综述了近年来AIH治疗方案的相关研究及潜在治疗靶点。
【Abstract】:Autoimmune hepatitis (AIH) is a liver inflammatory disease mediated by autoimmune response and may progress to liver failure and liver cirrhosis without treatment. The goal of AIH treatment is to achieve biochemical remission and histological remission. Currently immunosuppressant therapy is the standard therapy for AIH, i.e., prednisone/prednisolone alone or combined with azathioprine. For the patients who do not tolerate or have poor response to the standard therapy, second-line treatment regimen, including mycophenolate mofetil, can be considered. Recent studies have shown that various factors participate in the development and progression of AIH, such as immune function, gut microbiota, vitamin D, and mental state, which may become the potential therapeutic targets for AIH. This article reviews related studies on the standard therapies for AIH and highlights the potential therapeutic targets for AIH treatment.
【关键字】:肝炎,自身免疫性; 治疗学; 分子靶向治疗
【Key words】:hepatitis,autoimmune; therapeutics; molecular targeted therapy
【引证本文】:WANG R, WANG Q, MA X. Standard therapy and potential therapeutic targets for autoimmune hepatitis[J]. J Clin Hepatol, 2020, 36(4): 737-742. (in Chinese)
王睿, 王绮夏, 马雄. 自身免疫性肝炎的标准治疗和潜在治疗靶点[J]. 临床肝胆病杂志, 2020, 36(4): 737-742.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号